Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Thursday, October 3, 2013

Biogen Idec: New Analyses Show Tysabri Given Earlier Reduces MS Disease Activity

By RTT News,  October 03, 2013


(RTTNews.com) - Biogen Idec ( BIIB ) Thursday announced results from several new analyses of Tysabri (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis or MS disease activity.

According to the drugmaker, this effect was particularly significant in people with relapsing MS who initiated treatment when they had lower Expanded Disability Status Scale or EDSS scores as well as in those who have been treated for more than two years.

Alfred Sandrock, group senior vice president, Development Sciences and Chief Medical Officer, Biogen Idec, said, "These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease, as well as when TYSABRI is used for a longer duration in appropriate patients."

These data will be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis or ECTRIMS in Copenhagen, Denmark from October 2-5.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com
This article appears in: News Headlines

Source: Nasdaq






……..

To comment - click the comment link shown below
…….
USE OUR SHARE LINKS at the top of this page  - to provide this article to others
……
REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
…………………….
.

No comments: